eccancer | Reg: 08539058 | Created: 2013-05-22 | Status: active | Type: ltd ecancer is a dormant company established in Clifton, England, focused on research and development within the prostate cancer field. Founded in 2013, its initial focus centered around analyzing complex genomic data to identify novel therapeutic targets. The company’s core expertise lies in bioinformatics, statistical modelling, and interpretation of large-scale patient datasets. ecancer currently operates as a specialist consultancy providing expert analysis and predictive modeling services to pharmaceutical companies, research institutions, and healthcare providers specializing in prostate cancer treatment. Their primary service offering involves identifying potential biomarkers for early detection and personalized medicine approaches. The company’s key focus is on improving diagnostic accuracy and optimizing patient outcomes through advanced data mining techniques. ecancer maintains a strong international presence, actively seeking collaborations with global organizations and research facilities. While currently inactive, the company retains significant intellectual property related to its initial research projects. eccancer's SIC codes encompass several industries including: Healthcare & Pharmaceuticals (specifically oncology), Data Science & Analytics, Research & Development, and Consulting Services.

eccancer | Reg: 08539058 | Created: 2013-05-22 | Status: active | Type: ltd ecancer is a dormant company established in Clifton, England, focused on research and development within the prostate cancer field. Founded in 2013, its initial focus centered around analyzing complex genomic data to identify novel therapeutic targets. The company’s core expertise lies in bioinformatics, statistical modelling, and interpretation of large-scale patient datasets. ecancer currently operates as a specialist consultancy providing expert analysis and predictive modeling services to pharmaceutical companies, research institutions, and healthcare providers specializing in prostate cancer treatment. Their primary service offering involves identifying potential biomarkers for early detection and personalized medicine approaches. The company’s key focus is on improving diagnostic accuracy and optimizing patient outcomes through advanced data mining techniques. ecancer maintains a strong international presence, actively seeking collaborations with global organizations and research facilities. While currently inactive, the company retains significant intellectual property related to its initial research projects. eccancer's SIC codes encompass several industries including: Healthcare & Pharmaceuticals (specifically oncology), Data Science & Analytics, Research & Development, and Consulting Services.